FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131426079> ?p ?o ?g. }

• W2131426079 endingPage "37315" @default.
• W2131426079 startingPage "37300" @default.
• W2131426079 abstract "Glioblastoma multiforme (GBM) is the most lethal brain tumor. Tumor relapse in GBM is inevitable despite maximal therapeutic interventions. Glioma stem cells (GSCs) have been found to be critical players in therapeutic resistance and tumor recurrence. Therapeutic drugs targeting GSCs may significantly improve GBM treatment. In this study, we demonstrated that arsenic trioxide (As2O3) effectively disrupted GSCs and inhibited tumor growth in the GSC-derived orthotopic xenografts by targeting the promyelocytic leukaemia (PML). As2O3 treatment induced rapid degradation of PML protein along with severe apoptosis in GSCs. Disruption of the endogenous PML recapitulated the inhibitory effects of As2O3 treatment on GSCs both in vitro and in orthotopic tumors. Importantly, As2O3 treatment dramatically reduced GSC population in the intracranial GBM xenografts and increased the survival of mice bearing the tumors. In addition, As2O3 treatment preferentially inhibited cell growth of GSCs but not matched non-stem tumor cells (NSTCs). Furthermore, As2O3 treatment or PML disruption potently diminished c-Myc protein levels through increased poly-ubiquitination and proteasome degradation of c-Myc. Our study indicated a potential implication of As2O3 in GBM treatment and highlighted the important role of PML/c-Myc axis in the maintenance of GSCs." @default.
• W2131426079 created "2016-06-24" @default.
• W2131426079 creator A5018850815 @default.
• W2131426079 creator A5021296578 @default.
• W2131426079 creator A5022122158 @default.
• W2131426079 creator A5022362832 @default.
• W2131426079 creator A5030068217 @default.
• W2131426079 creator A5050147790 @default.
• W2131426079 creator A5060142050 @default.
• W2131426079 creator A5065575667 @default.
• W2131426079 creator A5075733723 @default.
• W2131426079 creator A5079256658 @default.
• W2131426079 creator A5089666742 @default.
• W2131426079 date "2015-10-14" @default.
• W2131426079 modified "2023-10-15" @default.
• W2131426079 title "Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth" @default.
• W2131426079 cites W1600827267 @default.
• W2131426079 cites W1964323367 @default.
• W2131426079 cites W1966048716 @default.
• W2131426079 cites W1967415817 @default.
• W2131426079 cites W1975618803 @default.
• W2131426079 cites W1985323012 @default.
• W2131426079 cites W1991582633 @default.
• W2131426079 cites W1993366604 @default.
• W2131426079 cites W2004874843 @default.
• W2131426079 cites W2005437050 @default.
• W2131426079 cites W2008793606 @default.
• W2131426079 cites W2010884432 @default.
• W2131426079 cites W2016299063 @default.
• W2131426079 cites W2016515708 @default.
• W2131426079 cites W2019768326 @default.
• W2131426079 cites W2021536610 @default.
• W2131426079 cites W2023033376 @default.
• W2131426079 cites W2023846533 @default.
• W2131426079 cites W2026480865 @default.
• W2131426079 cites W2027085235 @default.
• W2131426079 cites W2027102742 @default.
• W2131426079 cites W2031182614 @default.
• W2131426079 cites W2037209340 @default.
• W2131426079 cites W2037632266 @default.
• W2131426079 cites W2039075677 @default.
• W2131426079 cites W2044229112 @default.
• W2131426079 cites W2052246089 @default.
• W2131426079 cites W2052440970 @default.
• W2131426079 cites W2054413834 @default.
• W2131426079 cites W2056216914 @default.
• W2131426079 cites W2060551076 @default.
• W2131426079 cites W2060552146 @default.
• W2131426079 cites W2064484411 @default.
• W2131426079 cites W2066561957 @default.
• W2131426079 cites W2071534620 @default.
• W2131426079 cites W2073586533 @default.
• W2131426079 cites W2078510083 @default.
• W2131426079 cites W2099064703 @default.
• W2131426079 cites W2100200896 @default.
• W2131426079 cites W2101332957 @default.
• W2131426079 cites W2107823969 @default.
• W2131426079 cites W2110631752 @default.
• W2131426079 cites W2111504523 @default.
• W2131426079 cites W2112725705 @default.
• W2131426079 cites W2134819449 @default.
• W2131426079 cites W2139460080 @default.
• W2131426079 cites W2144867791 @default.
• W2131426079 cites W2149433168 @default.
• W2131426079 cites W2152387543 @default.
• W2131426079 cites W2159948826 @default.
• W2131426079 cites W2165935184 @default.
• W2131426079 cites W2166637572 @default.
• W2131426079 cites W2167650288 @default.
• W2131426079 cites W2168414172 @default.
• W2131426079 cites W2170325085 @default.
• W2131426079 cites W2324463016 @default.
• W2131426079 cites W2334267798 @default.
• W2131426079 cites W4255289481 @default.
• W2131426079 doi "https://doi.org/10.18632/oncotarget.5836" @default.
• W2131426079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4741931" @default.
• W2131426079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26510911" @default.
• W2131426079 hasPublicationYear "2015" @default.
• W2131426079 type Work @default.
• W2131426079 sameAs 2131426079 @default.
• W2131426079 citedByCount "41" @default.
• W2131426079 countsByYear W21314260792012 @default.
• W2131426079 countsByYear W21314260792014 @default.
• W2131426079 countsByYear W21314260792016 @default.
• W2131426079 countsByYear W21314260792017 @default.
• W2131426079 countsByYear W21314260792018 @default.
• W2131426079 countsByYear W21314260792019 @default.
• W2131426079 countsByYear W21314260792020 @default.
• W2131426079 countsByYear W21314260792021 @default.
• W2131426079 countsByYear W21314260792022 @default.
• W2131426079 crossrefType "journal-article" @default.
• W2131426079 hasAuthorship W2131426079A5018850815 @default.
• W2131426079 hasAuthorship W2131426079A5021296578 @default.
• W2131426079 hasAuthorship W2131426079A5022122158 @default.
• W2131426079 hasAuthorship W2131426079A5022362832 @default.
• W2131426079 hasAuthorship W2131426079A5030068217 @default.
• W2131426079 hasAuthorship W2131426079A5050147790 @default.
• W2131426079 hasAuthorship W2131426079A5060142050 @default.

• next